Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study

Merlano, Marco; Russi, Elvio; Benasso, Marco; Corvò, Renzo; Colantonio, I.; Vigna‐Taglianti, Riccardo; Vigo, V.; Bacigalupo, Almalina; Numico, Gianmauro; Crosetto, Nicola; Gasco, Milena; Nigro, Cristiana Lo; Vitiello, R.; Violante, S.; Garrone, Ornella

doi:10.1093/annonc/mdq412

Cited by 68 publications

(44 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regimens that include cetuximab [33,36,[48][49][50] and erlotinib [33] have shown ORRs in excess of 70%, with a manageable increase in toxicities. The phase II REACH study is currently investigating RT/carboplatin/5-FU plus cetuximab [49], with preliminary results indicating a promising ORR of 92.9% and 2-year PFS of 63.3% [50].…”

Section: Definitive Therapy For Unresectable Diseasementioning

confidence: 99%

Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck

Iberri

Colevas

2015

The Oncologist

View full text Add to dashboard Cite

The epidermal growth factor receptor (EGFR) is overexpressed in more than 80% of squamous cell cancers of the head and neck (SCCHN). An evolving understanding of the role of EGFR in tumorigenesis has made the receptor an important therapeutic target in SCCHN. Several EGFR inhibitors (EGFRIs) are active in SCCHN, and their use is associated with improvement in progression-free survival and overall survival in various treatment settings. Nevertheless, EGFR inhibition is associated with significant mucocutaneous toxicity that must be balanced against its anticipated efficacy. This review summarizes the relevant clinical trial experience with EGFRIs, with attention to efficacy, toxicity, and methods of selecting patients most likely to benefit from therapy.

show abstract

Section: Definitive Therapy For Unresectable Diseasementioning

confidence: 99%

Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck

Iberri

Colevas

2015

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Merlano et al [23] coordinated a study with 45 stage III-IV patients who received 3 cycles of cisplatin (20 mg/m 2 /day) and 5-FU (200 mg/m 2 /day) during 5 days, alternating with 3 divided courses and RT up to 70 Gy concomitantly with CTX at conventional weekly doses. CR was 71%, and median PFS and OS were 21 and 32.6 months, respectively.…”

Section: Resultsmentioning

confidence: 99%

Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab

Granados-García

Aguilar-Ponce²,

Maldonado-Magos³

et al. 2016

ORL

View full text Add to dashboard Cite

We review clinical trials of squamous cell carcinoma of the head and neck (SCCHN) to address the current and potential uses of cetuximab (CTX). PubMed was reviewed to identify papers published between 2010 and 2016. The search terms used were “cetuximab” and “head and neck cancer.” A total of 634 articles were identified. Phase II or III studies with CTX in patients with advanced SCCHN without treatment or with recurrent/metastatic tumors were selected. Forty-six registries were obtained. Information was critically reviewed and relevant information presented. As definitive treatment of advanced squamous cells carcinomas and as palliative treatment of recurrent/metastatic disease, CTX alone or associated with chemotherapy and/or radiotherapy is an alternative to chemoradiotherapy because of its distinct and favorable toxicity profile.

show abstract

“…In an Italian study, Merlano et al have evaluated the combination of 3 cycles of every 3-weeks cisplatin (20 mg/m2/day X 5 days) and 5-fluorouracil (200 mgm2/day X 5 days) with weekly cetuximab and rapidly alternated to 3 split courses of RT (70 Gy) (Merlano et al, 2011). In 45 patients treated, the overall RR was 91% with a CR rate of 71%.…”

Section: Cetuximab and Chemoradiotherapymentioning

confidence: 99%

Novel Chemoradiotherapy Regimens Incorporating Targeted Therapies in Locally Advanced Head and Neck Cancers

Rathore¹

2012

Head and Neck Cancer

View full text Add to dashboard Cite

A forest plot analysis was done to assess whether certain patient groups benefitted with the addition of cetuximab to RT. In this analysis, factors which were associated with a potential increased benefit included presence of oropharyngeal tumors, concomitant boost RT, early T stage (T1-T3), high Karnofsky performance score (90%-100%), male sex, and age < 65 years. These results are provocative but given that the trial was not powered for this subgroup analysis, they should be interpreted with caution.Patients who received cetuximab commonly developed an acneiform rash (83.7%); the severity of the rash was grade 3-4 in 16.8% patients. Infusion-related reactions were also seen in 15.4% patients; in 3.9% patients these were of grade 3/4 severity. However, in-field toxicities, such as mucositis, dermatitis, and dysphagia did not significantly increase with the addition of cetuximab to RT. Quality-of-life parameters were not adversely affected by the addition of cetuximab. This study allowed different RT fractionation regimens which may have impacted results and survival outcomes.

show abstract

Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study

Cited by 68 publications

References 37 publications

Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck

Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck

Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab

Novel Chemoradiotherapy Regimens Incorporating Targeted Therapies in Locally Advanced Head and Neck Cancers

Contact Info

Product

Resources

About